NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.abeonatherapeutics.comThe expected completion date for the Phase I/II/III gene transfer clinical trial of scAAV9.U1a.hSGSH is set for July 1, 2027. Sponsored by Ultragenyx Pharmaceutical Inc., this open-label, dose-escalation trial aims to evaluate the safety and efficacy of UX111 in treating conditions related to hSGSH deficiencies. The trial is currently in the recruitment phase with a total of 36 participants enrolled. The product has transitioned from Abeona Therapeutics to Ultragenyx as of August 2022, indicating strategic realignment within the pharmaceutical landscape. The outcome of this trial may have material implications for Ultragenyx's product pipeline and investor sentiment.
clinical trial completionAbeona Therapeutics, Inc has announced the expected completion date of a long-term extension study for EB-101, a gene therapy aimed at treating recessive dystrophic epidermolysis bullosa (RDEB). The study, which involves up to 22 participants previously treated with EB-101, will assess patient-reported outcomes and safety over a follow-up period of at least five years. This trial follows interventional work that applied gene-corrected keratinocyte sheets for wound management. Upon completion, participants will enter a ten-year annual monitoring program. The study is currently enrolling participants by invitation and is set to be completed by August 1, 2036.
Clinical Trial Completion